In patients with biliary tract cancer with a BRAF mutation, treatment with dabrafenib plus trametinib shrank tumors, results from a phase 2 trial show.
In patients with biliary tract cancer with a BRAF mutation, treatment with dabrafenib plus trametinib shrank tumors, results from a phase 2 trial show.
Comments are closed.